Home
overview

SAE Media Group’s 4th Annual Conference
AI in Drug Discovery
13-14 March, 2023 | Conference
-------------------------------------------------------------------------

With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts.

AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
 

  • DELVE into key industry research focuses, with talks on fragment-based selection, in silico drug design and personalised medicine from GSK, Bayer, Janssen Pharmaceuticals and more
  • INCREASE the diversity of your drug discovery programme with case studies in applying knowledge graphs, molecular dynamic simulations, and digital  twins throughout the development process
  • UTLISE breakthroughs in robotics, automation and quantum chemical methods alongside AI to drive the next generation of drug discovery
  • UNCOVER the role that international cooperation and open-source data played in the rapid development of Covid-19 treatments, and how this can be an example for the future of pharmaceutical R&D
  • LEARN how to implement AI and Machine Learning  techniques throughout the discovery pipeline from antigens and genomics to proteins and peptides

 

Key job titles include:

  • Head of AI
  • Head of Informatics
  • Head of Data
  • Head of Computational and Systems Toxicology
  • Director/Head of Strategic Data & Digital
  • Director/Head of Medicinal Chemistry
  • Director/Head of Molecular Design
  • Director/Head of Computational Chemistry
  • Director/Head of Chemical Sciences
  • Director of Therapeutic Technology
  • Chief Information Scientist
  • Chief Scientific Officer
  • Principal Scientist (Computational/Medicinal Chemistry)
  • Senior Application Scientist
  • Senior Research Scientist
  • Senior Bioinformatician
  • Molecular Modelling Team Leader
  • Data Team Leader

Previous Attendees Include:

 

AI for Good Foundation; Astex Pharmaceuticals; Astrazeneca; Basecamp Research; Bayer AG; Benevolent AI; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Research UK; CAS; CAS - Chemical Abstracts Services; CHARM Therapeutics; ChemAxon Ltd; Cresset Group; Cyclica; DISCNGINE; Envisagenics; e-Therapeutics PLC; Excsientia; Exscientia; Exscientia AI Limited; Galapagos; GB Sciences, Inc.; Genetech Inc; GENMAB; Glamorous AI; GSK; Healx Limited; KSM; leadXpro AG; Merck; Multiomic Health; Optibrium; Optibrium Ltd.; Pfizer; Schrodinger ; Schrodinger GmbH; Servier Pharmaceuticals; Sosei Heptares / Orexia Therapeutics; The Conference Board, Inc.; University Of Edinburgh; Verge Genomics;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Applying AI/ML in the drug discovery processes from hypothesis testing to preclinical screening

Darren Green

Darren Green, Head of Cheminformatics & Data Science, Senior Felllow, GSK
View Bio

• Overcoming the challenges currently facing pharmaceutical R&D programmes with data science and AI
• Opportunities for data analysis and predictive modelling in drug discovery
• Profitable applications to translate AI/ML from the lab to the clinic
• Open data sharing? - The importance of long-term planning
 

9:50 Transforming CNS and Oncology treatments with fragment-based drug discovery

Chris Murray

Chris Murray, SVP Discovery Technology, Astex Pharmaceuticals
View Bio

  • Implementing the PyramidTM platform for fragment-based drug discovery
  • Application of machine learning to structure-based drug design
  • Case study data from Astex’s Oncology and CNS programmes
  •  

    10:30 Morning Coffee

    11:00 Exploration of Chemical Space for Drug Lead Discovery and Optimization

    Paul Beroza

    Paul Beroza, Distinguished Scientist, Genentech
    View Bio

  • Strategies for chemical space exploration
  • Large-scale structure-based virtual screening
  • Generative design strategies for drug lead discovery and optimization
  • Characteristics of AI-generated latent chemical spaces
  • 11:40 Digital Twins- The face of the future of Pharmaceutical R&D

    Christos Varsakelis

    Christos Varsakelis, Associate Director Artificial Intelligence/Machine Learning, Janssen Pharmaceuticals
    View Bio

  • Current state of play and the potential of DTs for drug discovery
  • Overcoming the current challenges facing digital twins 
  • Regulatory considerations for the use of DTs
  • A look to the future- The Business Case for early adoption
  • 12:20 Networking Lunch

    13:20 Improving oligonucleotide molecular design using knowledge graphs

    Thierry Dorval

    Thierry Dorval, Head of Data Sciences & Data Management, Servier
    View Bio

  • Optimising drug discovery using computational approaches across organs
  • Case Studies from Servier’s drug design approach 
  • Ensuring adverse effect identification using AI approaches
  • Maximizing translatability to clinical data- The future of Knowledge Graph use
  • 14:00 Maximising potential for drug discovery approaches with holistic structure-based approaches

    Alexander Hillisch

    Alexander Hillisch, Vice President, Head of Computational Molecular Design, Bayer AG
    View Bio

  • Comparison of the holistic workflow to traditional processes and the role that AI/ML has played to develop this
  • ML models for predictions based on experimental ADMET and chemical synthesis data
  • Application examples from active drug discovery projects
  • Computational hit-finding experiments- The importance of public-private partnership
  • 14:40 Afternoon Tea

    15:10 Advancing structural discovery with biophysics and molecular dynamics simulations

    Matthias Frech

    Matthias Frech, Director Molecular Interactions and Biophysics, Merck KGaA

  • Improving implementation of complex AI in simulation assessments
  • Implementing artificial intelligence for protein engineering and design
  • Optimising compound prioritization with AI-derived analysis
  • Reactivity analysis using AI techniques

     

  • 15:50 AI/ML Driven Discovery of Splicing Derived Neoantigens

    Martin Akerman

    Martin Akerman, Chief Technical Officer, Envisagenics
    View Bio

  • Transparent guidelines to development of AI/ML features to allow more streamlined discovery feedback and processes
  • Introduction to Envisageincs’ SpliceIO platform: machine learning ensemble for the identification of RNA splicing derived neoantigens 
  • Case study: novel transmembrane neopeptide in triple negative breast cancer (ENV-21)
  • 16:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    9:10 The current state of play for Data and AI in drug discovery

    Andreas Bender

    Andreas Bender, Consultant, HealX
    View Bio

  • Considering the current issues in the field and what is needed to overcome these
  • The importance of open data sharing including failed results
  • Case Studies from the current use of AI for drug discovery
  • Improving AI in Drug Discovery and how to move forward
  • 9:50 Application of AI and Quantum Chemical Methods in a Pharmaceutical Environment

    Jan Wenzel

    Jan Wenzel, Scientist Computational and Systems Toxicology, Sanofi-Aventis Deutschland GmbH

  • ADME-Tox prediction using deep neural networks (DNN)
  • Comparison of different DNN methods
  • Applicability in a pharmaceutical environment
  • Computational quantum chemistry approach to assess the reactivity of N-Nitrosamine impurities
     
  • 10:30 Morning Coffee

    11:00 Operation Moonshoot- How AI based CADD helped the search for Covid-19 treatments

    Jag Heer

    Jag Heer, Director of Medicinal Chemistry, UCB
    View Bio

  • Harnessing the power of CADD to rapidly decode complex biology
  • Bridging knowledge- and structure-based approaches to enable greater predictive performance and expedite drug discovery cycle
  • Integration of data-driven research with wise experimental target validation approaches
  • Effective international collaboration with AI drug design

     

  • 11:40 How was AI used for predicting drug interaction properties?

    Venkatesh Pilla Reddy

    Venkatesh Pilla Reddy, Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca

  • The current state of play for Machine Learning predictions
  • Comparison of machine learning techniques
  • Strategic applications for AI and ML
  • Case Study for Safety Predictions
     
  • 12:20 Networking Lunch

    13:20 Closing the loop by combining wet lab automation and machine learning for accelerated program progression from target to hit, lead, and candidate • The Design-Make-Test-Analyse cycle is central for drug discovery, driving compound design and selection

    Martin-Immanuel Bittner

    Martin-Immanuel Bittner, Co-Founder and CEO, Arctoris
    View Bio

  • Right now, cycle times are long, and only a fraction of drug-like chemical space is being evaluated
  • Combining wet lab automation with machine learning allows us to close the loop in the discovery phase, with rapid, iterative data generation synergizing with a more efficient exploration of a wider chemical space
  • This enables an accelerated progression from target to high-quality hit, lead, and candidate
  • 14:00 Cellular Drug Discovery Platform “Mahol-A-Ba” Integrating Humans, AI, and Robots

    Haruna Iwaoka

    Haruna Iwaoka, Senior Director, Astellas Pharma
    View Bio

  • Integrating humans, AI and robots enables the development of high-quality drugs in a shorter time 
  • Developed cellular drug discovery platform “Mahol-A-Ba”, to utilize iPS cells for drug discovery
  • How “Mahol-A-Ba” enable us to do things that were previously impossible with human power alone
  • How to provide clearer and more precise results utilizing AI in our image processing technology

     

  • 14:40 Afternoon Tea

    15:10 Patient-focused precision medicine: creating better treatment options for unmet medical needs

    Steve Gardner

    Steve Gardner, CEO, PrecisionLife
    View Bio

  • Discovering novel drug targets with genetic linkage for complex diseases
  • Precision repositioning of existing drugs to treat additional diseases
  • Biomarkers to select the right patients for successful clinical trials
  • Accurately diagnosing patients and selecting the most effective medicines
     
  • 15:50 Advancing precision therapeutics with the integration of patient data, biomarkers, and AI

    Ed Addison

    Ed Addison, Chairman and CEO, Cloud Pharmaceuticals

  • Developing a novel approach to treatment plans with the augmentation of AI and big data screening
  • How the cloud pharmaceuticals technology considers traditional targeted therapeutics, but also polypharmacy, repurposing, and modulated biology discovery paradigms to implement with AI
  • Eliminating the need for drug design programmes with strategic implementation of AI for drug repositioning
  • Case Study results from Cloud Pharma’s partnerships with Drug Logic and Perthera
  • 17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Alexander Hillisch

    Alexander Hillisch

    Vice President, Head of Computational Molecular Design, Bayer AG
    Andreas Bender

    Andreas Bender

    Consultant, HealX
    Chris Murray

    Chris Murray

    SVP Discovery Technology, Astex Pharmaceuticals
    Christos Varsakelis

    Christos Varsakelis

    Associate Director Artificial Intelligence/Machine Learning, Janssen Pharmaceuticals
    Darren Green

    Darren Green

    Head of Cheminformatics & Data Science, Senior Felllow, GSK
    Haruna Iwaoka

    Haruna Iwaoka

    Senior Director, Astellas Pharma
    Jag Heer

    Jag Heer

    Director of Medicinal Chemistry, UCB
    Jan Wenzel

    Jan Wenzel

    Scientist Computational and Systems Toxicology, Sanofi-Aventis Deutschland GmbH
    Martin Akerman

    Martin Akerman

    Chief Technical Officer, Envisagenics
    Martin-Immanuel Bittner

    Martin-Immanuel Bittner

    Co-Founder and CEO, Arctoris
    Paul Beroza

    Paul Beroza

    Distinguished Scientist, Genentech
    Steve Gardner

    Steve Gardner

    CEO, PrecisionLife
    Thierry Dorval

    Thierry Dorval

    Head of Data Sciences & Data Management, Servier
    Venkatesh Pilla Reddy

    Venkatesh Pilla Reddy

    Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca

    Alexander Hillisch

    Vice President, Head of Computational Molecular Design, Bayer AG
    Alexander Hillisch

    Alexander Hillisch is a Vice President and Head of Computational Molecular Design at Bayer AG, Wuppertal, Germany. His team supports small molecule and biologics drug discovery in cardiology with computational chemistry, chemoinformatics, machine learning, in silico ADMET and structural bioinformatics techniques.
    From 1998 to 2003 he headed a research group at EnTec GmbH, Jena, Germany, a subsidiary of Schering AG, Berlin. There he was project manager in preclinical research and involved in the computer-aided design and pharmacological characterization of drugs against gynecological diseases and cancer.
    He conducted his Ph.D. thesis at the Institute of Molecular Biotechnology (IMB), Jena in the area of biophysics (NMR, FRET) and molecular modeling. Alexander Hillisch received his Ph.D. in Biochemistry with Prof. Peter Schuster in 1998 and his diploma in Pharmacy in 1995 from the University of Vienna, Austria.
    He is co-author of 44 research papers, 2 books and 62 pharmaceutical compound patents which led to 6 clinical development candidates. Alexander teaches “Molecular pharmacology and Drug Design” at the University of Cologne from which he received a honorary professorship in 2010.
     

    Andreas Bender

    Consultant, HealX
    Andreas Bender


    Dr Andreas Bender is a Professor for Molecular Informatics at Cambridge University, working on data analysis methods related to compound safety and efficacy, and Chief Technology & Informatics Officer (CITO) at PangeAI, part of Pangea Botanica. Previously he was a Director for Digital Life Sciences at Nuvisan in Berlin, as well as as an Associate Director for Data Science and AI in the Clinical Pharmacology & Safety Sciences group at AstraZeneca. On the entrepreneurial side, Andreas was involved in setting up Healx Ltd. (for data-driven drug repurposing) and PharmEnable Ltd. (for designing novel chemistry for targets that are difficult to drug conventially), both based in Cambridge/UK. He received his PhD from the University of Cambridge and worked in the Lead Discovery Informatics group at Novartis in Cambridge/MA as well as at Leiden University in the Netherlands before his current post.
     

    Chris Murray

    SVP Discovery Technology, Astex Pharmaceuticals
    Chris Murray

    Chris Murray studied for his undergraduate degree and doctorate at the University of Cambridge. After a post-doc at Indiana University, he joined the Biotech company, Protherics, where he helped develop docking methods and applied structure based drug design to serine proteases such as Factor Xa. In 2000 he joined Astex Pharmaceuticals where he now serves as SVP of Informatics. At Astex, he has been heavily involved in establishing fragment-based approaches to drug discovery and he has acted as project leader on a number of drug discovery projects including the beta-secretase, hsp90, FGFR, DDR and ERK programs.

    Christos Varsakelis

    Associate Director Artificial Intelligence/Machine Learning, Janssen Pharmaceuticals
    Christos Varsakelis

    Christos is an experienced professional with a successful track record working for and leading global teams in multinational companies in the pharmaceutical, chemical, financial and education sector. He has extensive experience in spearheading Data Science and modelling efforts in the Industry 4.0 era.

    Darren Green

    Head of Cheminformatics & Data Science, Senior Felllow, GSK
    Darren Green

    Darren Green is Director of Molecular Design and Senior Fellow, GlaxoSmithKline. Based at Stevenage, his group specialises in the application of molecular design, data analysis, predictive modelling and chemoinformatics methods to drug discovery. Darren also leads the Compound Collection Enhancement strategy for GSK.
    Darren has a PhD in Theoretical Chemistry from the University of Manchester. He is a Fellow of the Royal Society of Chemistry and chair of the Advisory Board for the Hartree Centre, the UK national laboratory for high performance computing, simulation and cognitive science.
     

    Ed Addison

    Chairman and CEO, Cloud Pharmaceuticals
    Ed Addison

    Haruna Iwaoka

    Senior Director, Astellas Pharma
    Haruna Iwaoka

    Haruna Iwaoka is a Senior Director of Advanced Modeling & Assay-Discovery Intelligence, Astellas Pharma Inc. She leads digital transformation of drug testing platforms leveraging AI and robotics. She received the Ph.D. degrees in agricultural chemistry from Tokyo University of Agriculture, in 2019. She joined Yamanouchi Pharma (Former Astellas) after graduate school of Tokyo University of Agriculture in 1994. Ever since she had been engaged in target discovery in drug discovery research, assay development in compound screening and assay using iPSCs. Recently, she has attracted worldwide attention, such as the development of new platform "Mahol-A-Ba" (SLAS Technol. 2021;26(5): 441-453 )

    Jag Heer

    Director of Medicinal Chemistry, UCB
    Jag Heer

    Jag carried out postdoctoral research with Professor Steve Ley, FRS, working on the total synthesis of rapamycin. In 1997 he joined SmithklineBeecham as a medicinal chemist. In 2009 he joined UCB in Belgium as Director of Medicinal Chemistry working on CNS projects. In 2015 he relocated to UCB Slough to work on immunology and inflammation NCE projects. He has a broad range of interests from hit identification to candidate selection, working at the interface of computational drug design, cheminformatics, and medicinal chemistry. He is associated with delivering clinical candidates in a number of therapeutic areas including CNS and cardiovascular disease and is a fellow of the Royal Society of Chemistry.

    Jan Wenzel

    Scientist Computational and Systems Toxicology, Sanofi-Aventis Deutschland GmbH
    Jan Wenzel

    Martin Akerman

    Chief Technical Officer, Envisagenics
    Martin Akerman

    Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.

     

    Martin-Immanuel Bittner

    Co-Founder and CEO, Arctoris
    Martin-Immanuel Bittner

    Martin-Immanuel Bittner, MD, DPhil, FRSA is the Chief Executive Officer of Arctoris, the drug discovery platform company that he co-founded in Oxford. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organizations, including EACR, AACR, and ESTRO. In recognition of his research achievements, he has been elected as a member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.

    Matthias Frech

    Director Molecular Interactions and Biophysics, Merck KGaA
    Matthias Frech

    Paul Beroza

    Distinguished Scientist, Genentech
    Paul Beroza

    Paul, a Distinguished Scientist in Computational Drug Discovery at Genentech, has over 20 years experience in computer-aided drug design and informatics in pharmaceutical research environments. He received his Ph.D. in Biophysics from UC San Diego and did postdoctoral work at the Scripps Research Institute. Before joining Genentech, he held several positions in Bay Area pharmaceutical companies including Senior Scientist Dupont Pharmaceuticals Research Labs, Director of Computational Sciences Telik, Inc. and Director of Computer-Aided Drug Design and Research Informatics Elan Pharmaceuticals. He has consulted in the areas of molecular modeling and 3D visualization technology and has over 40 patents and publications.

    Steve Gardner

    CEO, PrecisionLife
    Steve Gardner

    Steve is a serial technology entrepreneur with over 30 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors.

    Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies.

    He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies.

     

    Thierry Dorval

    Head of Data Sciences & Data Management, Servier
    Thierry Dorval

    Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens.
    In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.
     

    Venkatesh Pilla Reddy

    Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca
    Venkatesh Pilla Reddy

    Official Media Partner

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Media Partners


    Drug Discovery Today

    Official Media Partner
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

    Media Partners


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out